vs
Side-by-side financial comparison of AdvanSix Inc. (ASIX) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
AdvanSix Inc. is the larger business by last-quarter revenue ($359.9M vs $196.9M, roughly 1.8× Pacira BioSciences, Inc.). On growth, AdvanSix Inc. posted the faster year-over-year revenue change (9.4% vs 5.1%). Pacira BioSciences, Inc. produced more free cash flow last quarter ($43.5M vs $36.1M). Over the past eight quarters, Pacira BioSciences, Inc.'s revenue compounded faster (8.5% CAGR vs 3.4%).
AdvanSix Inc. is an American chemical company that produces nylon 6 and related chemicals such as caprolactam and ammonium sulfate fertilizers. It operated as Honeywell's Resins and Chemicals division until 2016, when it was spun off as a separate company. The unit accounted for 3 percent of Honeywell's sales at the time. For 2019, revenue is estimated at $1.4 billion. The company traces its lineage to the H. W. Jayne Company, established 1884 in Frankford, Pennsylvania.
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
ASIX vs PCRX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $359.9M | $196.9M |
| Net Profit | $-2.8M | — |
| Gross Margin | 7.6% | 79.5% |
| Operating Margin | -0.7% | 1.2% |
| Net Margin | -0.8% | — |
| Revenue YoY | 9.4% | 5.1% |
| Net Profit YoY | -892.9% | — |
| EPS (diluted) | $-0.11 | $0.05 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $359.9M | $196.9M | ||
| Q3 25 | $374.5M | $179.5M | ||
| Q2 25 | $410.0M | $181.1M | ||
| Q1 25 | $377.8M | $168.9M | ||
| Q4 24 | $329.1M | $187.3M | ||
| Q3 24 | $398.2M | $168.6M | ||
| Q2 24 | $453.5M | $178.0M | ||
| Q1 24 | $336.8M | $167.1M |
| Q4 25 | $-2.8M | — | ||
| Q3 25 | $-2.6M | $5.4M | ||
| Q2 25 | $31.4M | $-4.8M | ||
| Q1 25 | $23.3M | $4.8M | ||
| Q4 24 | $352.0K | — | ||
| Q3 24 | $22.3M | $-143.5M | ||
| Q2 24 | $38.9M | $18.9M | ||
| Q1 24 | $-17.4M | $9.0M |
| Q4 25 | 7.6% | 79.5% | ||
| Q3 25 | 6.8% | 80.9% | ||
| Q2 25 | 14.3% | 77.4% | ||
| Q1 25 | 14.2% | 79.7% | ||
| Q4 24 | 3.4% | 78.7% | ||
| Q3 24 | 14.4% | 76.9% | ||
| Q2 24 | 17.9% | 75.1% | ||
| Q1 24 | 0.9% | 71.6% |
| Q4 25 | -0.7% | 1.2% | ||
| Q3 25 | -0.9% | 3.5% | ||
| Q2 25 | 7.7% | 4.7% | ||
| Q1 25 | 7.7% | 1.2% | ||
| Q4 24 | -3.9% | 13.2% | ||
| Q3 24 | 7.5% | -82.8% | ||
| Q2 24 | 11.5% | 15.9% | ||
| Q1 24 | -7.0% | 7.9% |
| Q4 25 | -0.8% | — | ||
| Q3 25 | -0.7% | 3.0% | ||
| Q2 25 | 7.7% | -2.7% | ||
| Q1 25 | 6.2% | 2.8% | ||
| Q4 24 | 0.1% | — | ||
| Q3 24 | 5.6% | -85.1% | ||
| Q2 24 | 8.6% | 10.6% | ||
| Q1 24 | -5.2% | 5.4% |
| Q4 25 | $-0.11 | $0.05 | ||
| Q3 25 | $-0.10 | $0.12 | ||
| Q2 25 | $1.15 | $-0.11 | ||
| Q1 25 | $0.86 | $0.10 | ||
| Q4 24 | $0.02 | $0.38 | ||
| Q3 24 | $0.82 | $-3.11 | ||
| Q2 24 | $1.43 | $0.39 | ||
| Q1 24 | $-0.65 | $0.19 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $19.8M | $238.4M |
| Total DebtLower is stronger | — | $372.2M |
| Stockholders' EquityBook value | $815.2M | $693.1M |
| Total Assets | $1.7B | $1.3B |
| Debt / EquityLower = less leverage | — | 0.54× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $19.8M | $238.4M | ||
| Q3 25 | $23.7M | $246.3M | ||
| Q2 25 | $18.4M | $445.9M | ||
| Q1 25 | $8.3M | $493.6M | ||
| Q4 24 | $19.6M | $484.6M | ||
| Q3 24 | $17.3M | $453.8M | ||
| Q2 24 | $12.1M | $404.2M | ||
| Q1 24 | $20.6M | $325.9M |
| Q4 25 | — | $372.2M | ||
| Q3 25 | — | $376.7M | ||
| Q2 25 | — | $580.5M | ||
| Q1 25 | — | $583.4M | ||
| Q4 24 | — | $585.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $815.2M | $693.1M | ||
| Q3 25 | $818.2M | $727.2M | ||
| Q2 25 | $823.7M | $757.8M | ||
| Q1 25 | $794.4M | $798.5M | ||
| Q4 24 | $774.6M | $778.3M | ||
| Q3 24 | $766.4M | $749.6M | ||
| Q2 24 | $746.6M | $879.3M | ||
| Q1 24 | $713.2M | $892.2M |
| Q4 25 | $1.7B | $1.3B | ||
| Q3 25 | $1.7B | $1.3B | ||
| Q2 25 | $1.6B | $1.5B | ||
| Q1 25 | $1.6B | $1.6B | ||
| Q4 24 | $1.6B | $1.6B | ||
| Q3 24 | $1.5B | $1.5B | ||
| Q2 24 | $1.5B | $1.6B | ||
| Q1 24 | $1.5B | $1.6B |
| Q4 25 | — | 0.54× | ||
| Q3 25 | — | 0.52× | ||
| Q2 25 | — | 0.77× | ||
| Q1 25 | — | 0.73× | ||
| Q4 24 | — | 0.75× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $63.7M | $43.7M |
| Free Cash FlowOCF − Capex | $36.1M | $43.5M |
| FCF MarginFCF / Revenue | 10.0% | 22.1% |
| Capex IntensityCapex / Revenue | 7.7% | 0.1% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $6.4M | $136.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $63.7M | $43.7M | ||
| Q3 25 | $26.6M | $60.8M | ||
| Q2 25 | $21.1M | $12.0M | ||
| Q1 25 | $11.4M | $35.5M | ||
| Q4 24 | $64.2M | $33.1M | ||
| Q3 24 | $57.3M | $53.9M | ||
| Q2 24 | $50.2M | $53.2M | ||
| Q1 24 | $-36.2M | $49.1M |
| Q4 25 | $36.1M | $43.5M | ||
| Q3 25 | $66.0K | $57.0M | ||
| Q2 25 | $-7.2M | $9.3M | ||
| Q1 25 | $-22.6M | $26.9M | ||
| Q4 24 | $29.8M | $31.0M | ||
| Q3 24 | $26.8M | $49.8M | ||
| Q2 24 | $16.7M | $51.6M | ||
| Q1 24 | $-71.6M | $46.3M |
| Q4 25 | 10.0% | 22.1% | ||
| Q3 25 | 0.0% | 31.7% | ||
| Q2 25 | -1.7% | 5.1% | ||
| Q1 25 | -6.0% | 15.9% | ||
| Q4 24 | 9.1% | 16.6% | ||
| Q3 24 | 6.7% | 29.6% | ||
| Q2 24 | 3.7% | 29.0% | ||
| Q1 24 | -21.3% | 27.7% |
| Q4 25 | 7.7% | 0.1% | ||
| Q3 25 | 7.1% | 2.2% | ||
| Q2 25 | 6.9% | 1.5% | ||
| Q1 25 | 9.0% | 5.1% | ||
| Q4 24 | 10.4% | 1.1% | ||
| Q3 24 | 7.7% | 2.4% | ||
| Q2 24 | 7.4% | 0.9% | ||
| Q1 24 | 10.5% | 1.7% |
| Q4 25 | — | — | ||
| Q3 25 | — | 11.20× | ||
| Q2 25 | 0.67× | — | ||
| Q1 25 | 0.49× | 7.37× | ||
| Q4 24 | 182.29× | — | ||
| Q3 24 | 2.57× | — | ||
| Q2 24 | 1.29× | 2.82× | ||
| Q1 24 | — | 5.47× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ASIX
| Plant Nutrients | $140.0M | 39% |
| Chemical Intermediates | $92.8M | 26% |
| Caprolactam | $64.4M | 18% |
| Nylon Resins | $62.8M | 17% |
PCRX
| EXPAREL | $155.8M | 79% |
| ZILRETTA | $33.0M | 17% |
| Iovera | $7.0M | 4% |
